Effect analysis of entecavir on serum hyaluronic acid, laminin and IV collagen in the treatment of hepatitis B E-antigen-positive chronic hepatitis B.

Background: To observe and analyse the clinical effects of entecavir on serum hyaluronic acid (HA), laminin (LN), and type IV collagen (IVC) in patients with hepatitis B e-antigen (HBeAG)-positive chronic hepatitis B during clinical treatment.

Methodology: The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy. The clinical curative effects of immune checkpoint inhibitors at different concentrations on diseases were compared from all aspects.

Results: There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05). The levels of liver function indicators, immune function-related indicators (CD3+, CD4+, CD8+, CD4+/CD8+, CD4+/CD8+), and HA, LN and IVC were not statistically different between the two groups before treatment.

Conclusion: Entecavir is highly effective in the clinical treatment of HBeAG-positive chronic hepatitis B. However, entecavir + thymalfasin combination therapy can alleviate the clinical symptoms. In this way, liver fibrosis can be prevented in patients with HBeAG-positive chronic hepatitis B, and the clinical curative effect can be enhanced.